Theriva Biologics, Inc.
TOVX
$0.25
$0.014.52%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 152.74% | 132.79% | 124.06% | 127.53% | -14.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.66% | 29.18% | 27.40% | 22.30% | -19.39% |
| Operating Income | -21.99% | -29.18% | -27.40% | -22.30% | 19.39% |
| Income Before Tax | 13.52% | 7.46% | 3.41% | -27.28% | -21.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.52% | 7.46% | 1.88% | -32.72% | -30.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.52% | 7.46% | 1.88% | -32.72% | -30.34% |
| EBIT | -21.99% | -29.18% | -27.40% | -22.30% | 19.39% |
| EBITDA | -22.24% | -29.55% | -27.81% | -22.61% | 19.43% |
| EPS Basic | 87.65% | 84.77% | 83.29% | 61.80% | 28.17% |
| Normalized Basic EPS | 80.59% | 78.40% | 78.41% | 69.87% | 59.86% |
| EPS Diluted | 87.65% | 84.77% | 83.29% | 61.80% | 28.17% |
| Normalized Diluted EPS | 80.59% | 78.40% | 78.41% | 69.87% | 59.86% |
| Average Basic Shares Outstanding | 1,059.29% | 799.76% | 571.08% | 376.34% | 181.70% |
| Average Diluted Shares Outstanding | 1,059.29% | 799.76% | 571.08% | 376.34% | 181.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |